Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures. Thanx for your patience as we catch-up.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

ZafGen (Cambridge, MA) a clinical-stage company focused on small molecule therapeutics for the treatment of obesity, closed a $8.1M Series B financing, bringing the total round to $28M. Participants include Atlas Venture, Third Rock Ventures and GreatPoint Ventures.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, […]

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

  

to top of page...